Agenus Inc.
AGENStock
$5.00−25.62%52W
Market Cap$205.71M
P/E1788.81x
Div yield—
Beta1.54
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)37.72%
Price vs S&P 500 (4W)56.71%
VGM Score67.48
Market Capitalization$205.71M
P/E Ratio (Annual)1788.81x
Earnings Surprise History
Q1 260.00est. 2.14
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.13
4.13
4.13
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AGENAgenus Inc. | B | B | B | $5.00 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Agenus is a clinical-stage immunotherapy company developing therapies to activate the immune system against cancer and infectious disease. Its pipeline includes immune-modulatory antibodies (botensilimab, a CTLA-4 inhibitor; balstilimab, a PD-1 inhibitor), adoptive cell therapies through subsidiary MiNK Therapeutics, and vaccine adjuvants via subsidiary SaponiQx. The company operates in-house cGMP manufacturing and clinical operations capabilities to support product development.